Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. The Company's lead product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Tipifarnib is a new chemical entity, or NCE, and a member of a class of product candidates called farnesyl transferase inhibitors, or FTIs. Protein farnesylation is a key cell signaling process implicated in various cancer processes, including survival, growth and proliferation of tumor cells. 

Employee Rating

0More
TypePublic
HQSan Diego, US
Founded2007
Size (employees)34 (est)+14%
Websitekuraoncology.com
Kura Oncology was founded in 2007 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Kura Oncology Office Locations

Kura Oncology has an office in San Diego
San Diego, (HQ)
125 11119 N Torrey Pines Rd
Show all (1)
Report incorrect company information

Kura Oncology Financials and Metrics

Kura Oncology Revenue

USD

Net income (Q3, 2018)

(15.0m)

Market capitalization (12-Dec-2018)

550.0m

Closing stock price (12-Dec-2018)

14.5

Cash (30-Sep-2018)

20.6m

EV

535.7m
Kura Oncology's current market capitalization is $550 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

General and administrative expense

22.7k6.0m7.9m9.4m

R&D expense

13.9m16.6m25.1m

Operating expense total

22.7k23.9m28.4m36.1m

EBIT

(22.7k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

4.5k4.1k5.2k1.5m1.8m2.4m1.8m1.7m2.1m2.2m2.3m3.4m3.7m4.3m

R&D expense

3.3m3.6m3.6m4.0m4.3m5.2m5.2m6.8m11.3m11.1m11.5m

Operating expense total

4.5k4.1k5.2k5.9m6.4m7.0m6.8m7.1m7.7m7.9m9.5m15.0m15.3m16.0m

EBIT

(4.5k)(4.1k)(5.2k)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

6.6k5.6k15.4m9.7m11.4m

Accounts Receivable

92.4m

Inventories

693.0k725.0k

Current Assets

86.9m68.8m94.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

10.6k6.2k4.9k11.2m16.3m12.1m6.8m10.6m12.2m23.3m26.5m17.7m20.6m

Inventories

909.0k

Current Assets

42.3m80.1m81.4m75.7m60.6m54.7m101.9m140.4m128.5m190.4m

PP&E

78.0k62.0k55.0k47.0k32.0k24.0k17.0k5.0k1.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.6k)(30.7k)(22.6m)(27.6m)(35.4m)

Depreciation and Amortization

20.0k31.0k30.0k

Inventories

(42.0k)(32.0k)

Accounts Payable

(1.5k)2.1k2.8m471.0k3.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.6m)(66.0k)(6.6m)(6.7m)(6.9m)(7.5m)(9.3m)

Inventories

909.0k

Accounts Payable

650.0713.08.2k10.7k2.5m3.7m3.1m3.3m4.2m3.7m4.2m6.2m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Kura Oncology Operating Metrics

FY, 2016

Phase II Trials Products

1

Preclinical Phase Products

2
Show all operating metrics
Report incorrect company information

Kura Oncology News and Updates

Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL –

Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

– AITL patent expands protection for tipifarnib, provides exclusivity in U.S. to 2037 –
Report incorrect company information

Kura Oncology Blogs

Tyler Van Buren

Tyler Van Buren ma.celeste.loy… Thu, 11/15/2018 - 13:11 Tyler Van Buren Piper Jaffray & Co.

Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for

Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to

Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update

– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upcoming at ASH – – $187.4 million in cash, cash

Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO , Nov. 05, 2018 (GLOBE NEWSWIRE) --   Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the

Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting

SAN DIEGO , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company’s lead product candidate, tipifarnib, have been
Show more

Kura Oncology Company Life and Culture

Report incorrect company information

Kura Oncology Frequently Asked Questions

  • When was Kura Oncology founded?

    Kura Oncology was founded in 2007.

  • How many employees does Kura Oncology have?

    Kura Oncology has 34 employees.

  • Who are Kura Oncology competitors?

    Competitors of Kura Oncology include Inventiva, BioInvent and Orion.

  • Where is Kura Oncology headquarters?

    Kura Oncology headquarters is located at 125 11119 N Torrey Pines Rd, San Diego.

  • Where are Kura Oncology offices?

    Kura Oncology has an office in San Diego.

  • How many offices does Kura Oncology have?

    Kura Oncology has 1 office.